Michelson Diagnostic’s Multi Beam OCT technology to Provide Significant Cost Savings for Treating Non-Melanoma Skin Cancer
(Orpington, UK) April 29, 2010 – At a time where non-melanoma skin cancer is reaching epidemic proportions in the U.S, accounting for 4.5% of all Medicare cancer costs; there is a new breakthrough in skin imaging that is predicted to provide significant cost savings. Michelson Diagnostics, a leading innovator in Multi-Beam Optical Coherence Tomography (OCT) products, has developed the VivoSight scanner, which has shown great potential in pre-operation delineation of tumor margins in skin cancer patients. The scanner, which received 510 FDA Clearance in January, is able to provide extraordinarily high resolution images of tumors in real-time, to improve excision accuracy and reduce the number of repeat biopsies and Mohs cycles.
According to a recent study published in the Archives of Dermatology 1, non-melanoma skin cancer is now an epidemic in the U.S., with the estimated total number of such cancers in the U.S. population put at more than 3.5M in 2006 and rising 4% per year. The cost of treatment is significant, accounting for 4.5% of Medicare cancer costs, or over $1.6BN.
“The largest single contribution to the treatment cost is the surgical removal of the skin cancers,” says Jon Holmes, CEO of Michelson Diagnostics. “Therefore any improvement in the efficiency of operations could produce savings of hundreds of millions of dollars to the US healthcare system.”
A recent IRB approved, patient study conducted by Daniel Siegel, M.D., a Clinical Professor of Dermatology, SUNY Downstate, Private Practitioner and Incoming President-Elect of American Academy of Dermatology, reported success in using the company’s VivoSight scanner to differentiate between cutaneous tumors and normal epithelium stroma.
“Michelson’s VivoSight Multi-Beam OCT system appears to be able to differentiate cutaneous tumors from normal epithelium and stroma,” says Siegel. “While not yet of specific diagnostic value, it appears to be sensitive enough to give useful clinical data in real time, and has great potential in helping pre-operation delineation of tumor margins, which can be both a time and cost saver in the US Health System.”
Siegel described three ways in which the instrument could help in future.
During routine surgery, it would reduce the incidence of incomplete resection due to positive margins, where a patient has to have repeat surgery if the whole tumor wasn’t removed the first time. In addition, it would help make sure that cancer wasn’t mistakenly thought to be normal and left to develop.
In Mohs surgery, where real-time histology ensures complete tumor removal, OCT could help reduce the average number of stages necessary to achieve clearance.
The VivoSight scanner uses Multi-Beam OCT to provide images of surface tissue at extraordinarily high resolution – better than 7.5 µm lateral and 10 µm vertical resolution – far higher than is possible with other modalities, revealing previously hidden details of tissue microstructure. Multi-Beam OCT uses four laser beams to achieve double the lateral image resolution of conventional single-beam OCT, which is crucial to providing crisp, clear images of the subject matter micro-structure.
When the hand-held probe is positioned over the tissue it can capture either 2D or 3D images of a 5mm square region. Tissue microstructure features such as epidermis, dermis and sub-layers can be imaged, as can subsurface blood vessels. VivoSight captures and displays images in real time, for instant visual feedback. The captured video data can be instantly replayed for review, or stored for later analysis.
About Michelson Diagnostics
Michelson Diagnostics was founded in 2006; it is privately owned and based in Kent, U.K. The company develops imaging products using a technology called Multi-Beam Optical Coherence Tomography.
The company’s products include the EX1301 OCT Microscope which is used by researchers in a variety of fields including genetics research, tissue engineering and industrial metrology; and the VivoSight OCT scanner which has CE and 510(k) clearance for use to aid clinical judgments in the field of dermatology. Potential applications of VivoSight include non-melanoma skin cancer screening and guiding skin cancer surgery.
Further information about Michelson Diagnostics is available on the Internet at http://www.md-ltd.co.uk/ or by email to firstname.lastname@example.org.
1. H. W. Rogers, et al. (2010) Arch Dermatol, 146(3), pp. 283-7.
For clinical use in the US FDA 510(k) K093520 applies:
The VivoSight Topical OCT system is indicated for use in the two-dimensional, cross-sectional, real-time imaging of external tissues of the human body. This indicated use allows imaging of tissue microstructure, including skin, to aid trained and competent clinicians in their assessment of a patient's clinical conditions.
US Federal law restricts this device to sale by or on the order of a physician.
The Michelson Diagnostics logo and the VivoSight name are the trademarks of Michelson Diagnostics Ltd and are registered in the UK, the US & throughout the European Union.